453 related articles for article (PubMed ID: 30146342)
21. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
Yang X; Meng L; Zhong Y; Hu F; Wang L; Wang M
Aging (Albany NY); 2021 Jan; 13(2):2864-2884. PubMed ID: 33418541
[TBL] [Abstract][Full Text] [Related]
22. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
Mei J; Liu G; Li R; Xiao P; Yang D; Bai H; Hao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34821362
[TBL] [Abstract][Full Text] [Related]
23. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
Liu Y; Zhang Y; Li Q; Xu R; Huang N
Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
[TBL] [Abstract][Full Text] [Related]
24. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
[TBL] [Abstract][Full Text] [Related]
25. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
26. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
27. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
28. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
30. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
31. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of METTL14-mediated m
Gong S; Wang S; Shao M
J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
[TBL] [Abstract][Full Text] [Related]
33. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
34. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression.
Yin X; Liao Y; Xiong W; Zhang Y; Zhou Y; Yang Y
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):1049-1057. PubMed ID: 32173903
[TBL] [Abstract][Full Text] [Related]
36. Circ-CUL2/microRNA-888-5p/RB1CC1 axis participates in cisplatin resistance in NSCLC via repressing cell advancement.
Chen H; Li F; Xue Q
Bioengineered; 2022 Feb; 13(2):2828-2840. PubMed ID: 35068326
[TBL] [Abstract][Full Text] [Related]
37. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
Shao N; Song L; Sun X
Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
[TBL] [Abstract][Full Text] [Related]
38. MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.
Liu MX; Zhou KC; Cao Y
Mol Cancer; 2014 Nov; 13():245. PubMed ID: 25373388
[TBL] [Abstract][Full Text] [Related]
39. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Pang J; Ye L; Zhao D; Zhao D; Chen Q
Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
[TBL] [Abstract][Full Text] [Related]
40. PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer.
Tian R; Zhang C; Xiong F; Chen H
Front Biosci (Landmark Ed); 2020 Mar; 25(5):948-960. PubMed ID: 32114419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]